GoAI
Get started
Barinthus Biotherapeutics plc logo

Barinthus Biotherapeutics plc

BRNS

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.6217

+$0.0094 · +1.54%

Aug 21, 4:00 PM ET

Pre-market

$0.6001

−$0.0216 · -3.47%

Aug 24, 6:41 AM ET

BRNS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

27

Weakening

Sentiment

47

Mixed

Risk resilience

31

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
William James Enright
Listed since
Apr 30, 2021
Employees
14

Market position

Day range

Current $0.6217

52-week range

Current $0.6217

Open
$0.63
Previous close
$0.6123
Volume
11.68K
0.2× average
Average volume
59.33K
Average daily volume
Market cap
25.4M USD
Beta
-0.39
Market reference 1
50-day average
$0.6241
-0.38% below average
200-day average
$0.6694
-7.12% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-30.8M USD
P/E (TTM)
-0.6×
P/B (TTM)
0.44×
P/S (TTM)
0×
EV / EBITDA
0.49×
Earnings yield
-234.67%
Free cash flow yield
-169.23%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-89.73%
Return on assets
-67.83%
Return on invested capital
-58.20%

Financial health

Debt / equity
0.18×
Current ratio
7.77×
Altman Z-score
-5.8
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends2008%-5624%-13256%-20887%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Operating margin, FY2021: -16873.51%Operating margin, FY2022: -9.04%Operating margin, FY2023: -10463.09%Operating margin, FY2024: -454.07%Net margin, FY2021: -18979.48%Net margin, FY2022: 11.95%Net margin, FY2023: -9145.51%Net margin, FY2024: -408.00%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Operating margin FY2021 -16873.51%. Operating margin FY2022 -9.04%. Operating margin FY2023 -10463.09%. Operating margin FY2024 -454.07%. Net margin FY2021 -18979.48%. Net margin FY2022 11.95%. Net margin FY2023 -9145.51%. Net margin FY2024 -408.00%.

Income trends

Revenue

14.97M USD+1766.46%

Operating income

−54.19M USD+20.27%

Net income

−66.58M USD-9.02%
Income trends across reported periods57.56M USD6.12M USD−45.33M USD−96.78M USDRevenue, FY2021: 268K USDRevenue, FY2022: 44.7M USDRevenue, FY2023: 802K USDRevenue, FY2024: 14.97M USDOperating income, FY2021: −45.22M USDOperating income, FY2022: −4.04M USDOperating income, FY2023: −83.91M USDOperating income, FY2024: −67.97M USDOperating income, FY2025: −54.19M USDNet income, FY2021: −50.87M USDNet income, FY2022: 5.34M USDNet income, FY2023: −73.35M USDNet income, FY2024: −61.07M USDNet income, FY2025: −66.58M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 268K USD. Revenue FY2022 44.7M USD. Revenue FY2023 802K USD. Revenue FY2024 14.97M USD. Operating income FY2021 −45.22M USD. Operating income FY2022 −4.04M USD. Operating income FY2023 −83.91M USD. Operating income FY2024 −67.97M USD. Operating income FY2025 −54.19M USD. Net income FY2021 −50.87M USD. Net income FY2022 5.34M USD. Net income FY2023 −73.35M USD. Net income FY2024 −61.07M USD. Net income FY2025 −66.58M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue—14.97M USD802K USD44.7M USD268K USD
Cost of goods sold5.86M USD————
Gross profit−5.86M USD14.97M USD802K USD44.7M USD268K USD
Research and development25.56M USD38.25M USD41.41M USD41.11M USD16.37M USD
Selling, general, and administrative40.83M USD29.67M USD39.84M USD6.39M USD25.12M USD
Operating expenses48.34M USD82.94M USD84.72M USD48.74M USD45.49M USD
Interest income1.96M USD2.68M USD2.88M USD3.1M USD2K USD
Interest expense51.12K USD53K USD28K USD19K USD2.67M USD
Depreciation and amortization5.85M USD5.8M USD5.43M USD4.32M USD602K USD
Operating income−54.19M USD−67.97M USD−83.91M USD−4.04M USD−45.22M USD
Net income−66.58M USD−61.07M USD−73.35M USD5.34M USD−50.87M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
64%
7 beats, 4 misses, 0 met estimates
Average EPS surprise
+9.27%
11 comparable reports
Latest EPS result
-0.26
Estimate -0.28 · Beat by 7.14%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.12-0.27-0.41-0.56Q1 '25MissQ2 '25MissQ3 '25MissQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Mar 20, 2025: actual -0.51, estimate -0.5, surprise -2.00%, Miss. Q2 2025, reported May 7, 2025: actual -0.49, estimate -0.34, surprise -44.12%, Miss. Q3 2025, reported Aug 7, 2025: actual -0.52, estimate -0.29, surprise -79.31%, Miss. Q4 2025, reported Nov 7, 2025: actual -0.36, estimate -0.45, surprise +20.00%, Beat. Q1 2026, reported Mar 13, 2026: actual -0.27, estimate -0.4, surprise +32.50%, Beat. Q2 2026, reported Apr 30, 2026: actual -0.14, estimate -0.36, surprise +61.11%, Beat. Q3 2026, reported Aug 6, 2026: actual -0.26, estimate -0.28, surprise +7.14%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -0.25, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates16.9M7.57M-1.77M-11.1MQ1 '24BeatQ4 '24No estimateQ1 '25No estimateQ4 '26Estimate
Q1 2024, reported Mar 20, 2024: actual 5.37M USD, estimate 130K USD, surprise +4030.21%, Beat. Q4 2024, reported Nov 6, 2024: actual 14.97M USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 20, 2025: actual -9.17M USD, estimate —, surprise —, Comparison unavailable. Q4 2026, reported Nov 5, 2026: actual —, estimate 216.9K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$3.00

382.55% upside
Past 12 months12-month forecastHigh $3.00Average $3.00Low $3.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy375%
Hold125%
Sell00%
Strong sell00%

Recent analyst actions

4 institutions
Alliance Global PartnersmaintainBuy
BarclaysmaintainOverweight
Morgan StanleydowngradeOverweightEqual Weight

BRNS news

BRNS peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research BRNS

research.disclaimer